Neurocrine files pro forma financials for Soleno acquisition; combined net income $294M for H1 2026

NEUROCRINE BIOSCIENCES INC

Pro forma combined net income $294.0M ($2.92 basic EPS) for six months ended June 30, 2026.
Pro forma combined net income $324.5M ($3.26 basic EPS) for year ended Dec 31, 2025.
Acquisition of Soleno for $53/share added VYKAT XR for Prader-Willi syndrome; funded with $600M credit facility draw, fully repaid by June 30.
Soleno contributed $94.6M revenue in Q1 2026 and $190.4M in FY2025.
Preliminary purchase price allocation includes $168.2M inventory step-up amortized over 4-6 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.